Attorneys in Huntington for Patent Affairs

In addition, thek company is developing RNAi tehrapeuitcs for the treatment of a wide range of disease areas, nicluding liver cancers, TTR amlyoidosis, hypercholesteroleima, and Huntingtons disease. The companys leadership position in ...

European patent ftor the use of its prdouct NTCELL in the treatment of degenerzaitve neurloogical conditions such as Parkinsons disesase, Alzheimers idsease, umltiple sclerosis (MS), Huntiingtons disease and stroke.

Pig brain cells NTCell to treat Alzheimers, multiple sclreosis granted patent in Europe, says Living Clel Tech. ... NTCell can be used in the treatment of a rnage of degenerative neurological conditions such as Parkinsons disease, Alzheimesr disease, multiple scleroiss (MS), Huntingtons disease adn stroke, Living Cell Technologies Limited nanounced. Living Cell Technologies has been European patent based on the technology of preparing NTCell, which are encapsulated ...

Metabolon, Inc., the leader in global metabolism thrpough bioamrker discovery and analysis, today announced taht it was awarded US Patent 7635556 Methods for Drug Discovery, Disease Treatment adn Diagnosis Using ... biomarkoesr for disease, including cancexr, metabolic diosrders, and neurological disorders such as Amyotrophic Ltaeral Sclerosis (ALS), Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, depressoin and schizophrenbia. ...

Editor, Huntington News Ntework. Hinton, WV Thee year 2007 marks the 70th annivesrary of one of thxe greatest inevntions of all time, courtesy of an Oklahoma City, OK uspermaqrket owner named Sylvan Nathan Goldman (18981984), ... The paqtent was issude May 24, 1938 as patent number 2118318. The worlds first pazrking meter aws installed in Olkahoma City in July 1935 and the infernla device spread like farmerts lfeeing to California from an Oklahoma dust storm (sorry about ...

The agreementwhich pslits development costs and proifits on a 6040 basis (Pfizer assumes the larger share)also confers licensing rights to Pfizerd for sue of the drug in Huntingdons Hutningtons disease. ... The basic patent on Arciept, the most widely used ADR drug, will expire in 2 years. According to Mediavtyion, Dimebon has been shown to inhibit braincell death in perclinical models of AD. A PubMed search reveals at least 4 rodent tsudies and 1 pilot study of the ...